Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
Click here to view press release
Data from a Phase I/II Study Presented at the 32nd San Antonio Breast Cancer Symposium Suggest that INCB7839 in Combination with Trastuzumab May Improve Clinical Response Rates in HER2 Positive Patients with Advanced Metastatic Disease
Click here to view press release
Data from Three Phase II Trials to be Presented at the 51st American Society of Hematology Annual Meeting Demonstrate that INCB18424, a Selective JAK1/JAK2 Inhibitor, Has Potential in Multiple Hematology Conditions
Click here to view press release
Click here to view A Phase II Study of INCB018424 (PV/ET) Presentation
Click here to view Significant Activity of the JAK2 Inhibitor, INCB018424 (Leukemias) Presentation
Click here to view Long-Term Follow up and Optimized Dosing Regimen of INCB018424 (MF) Presentation
Click here to view poster information
Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs
Click here to view press release
To view or listen to our most recent corporate presentations, please use the link provided below
Click here for recent conferences and presentations
